No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Operating globally across India, the United States, South Africa, and other international markets, Cipla Limited, along with its affiliated entities, is engaged in the production, advancement, and distribution of pharmaceutical goods. Its operations are structured into two principal divisions: Pharmaceuticals and New Ventures. Beyond active pharmaceutical ingredients (APIs), the company delivers diverse formulations addressing a wide array of therapeutic areas. These encompass cardio-metabolic conditions (including treatments for MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities, diabetes, and obesity), HIV, respiratory disorders, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. Its specialized respiratory portfolio features inhalers and nasal sprays, complemented by other related offerings such as injectables and biosimilar treatments. A specific product noteworthy is Easylax and Easylax L, a liquid paraffin solution designed to alleviate constipation. Established in 1935, Cipla Limited maintains its corporate headquarters in Mumbai, India.
www.cipla.comNo one on the platform currently holds CIPLA.BO.
No tracked institution reports a position in CIPLA.BO as of their last filing.
No one on the platform has traded CIPLA.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 10.3% | 22.7% | 24.9% | — | — | — |
| Rev. Growth % | 3.3% | 8.1% | ||||
| Profit Margin % | 13.8% | 14.7% | 12.1% | |||
| Free Cash Flow Margin % | 9.0% | 11.0% | 10.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $309.3B | +9.2% | $51.07 | $40.11–$60.40 | — | 32 |
| 2028 | $347.0B | +12.2% | $63.88 | $56.34–$71.18 | — | 30 |
| 2029 | $379.4B | +9.3% | $71.75 | $63.37–$83.70 | — | 14 |
| 2030 | $431.7B | +13.8% | $107.70 | $99.94–$115.35 | — | 7 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-22 | $10.62 | $9.76 | -8.1% |
| 2026-05-13 | $9.80 | $6.86 | -30.0% |
| 2026-01-22 | $15.37 | $8.36 | -45.6% |
| 2025-10-29 | $16.18 | $16.72 | +3.3% |
| 2025-07-25 | $14.65 | $16.06 | +9.6% |
| 2025-05-12 | $12.19 | $15.10 | +23.9% |
| 2025-01-27 | $14.79 | $19.43 | +31.4% |
| 2024-10-28 | $14.95 |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| CIPLA.BOCipla Limited | $1361.00 | -0.29% | $1.11T | — |
| APOLLOHOSP.BOApollo Hospitals Enterprise Limited | $8700.00 | -1.69% | $1.25T | — |
| APOLLOHOSP.NSApollo Hospitals Enterprise Limited | $8714.00 | -1.38% | $1.25T | — |
| DRREDDY.BODr. Reddy's Laboratories Limited | $1149.75 | -0.97% | $966.0B | — |
| DRREDDY.NSDr. Reddy's Laboratories Limited |
| $16.12 |
| +7.8% |
| $1145.00 |
| -1.76% |
| $953.8B |
| — |
| LUPIN.BOLupin Limited | $2055.35 | -1.94% | $937.2B | — |
| LUPIN.NSLupin Limited | $2063.20 | -1.52% | $943.4B | — |
Source: Financial Modeling Prep · peers by sector/industry